Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe

Rhea-AI Summary

Nanox (NASDAQ: NNOX) announced a collaboration with Paris-based radiology group Olympe Imagerie to deploy the Nanox.ARC at Hospital Privé Jacques Cartier MASSY for lung cancer screening clinical trials, dated Nov 14, 2025. The Nanox.ARC, a multi-source digital tomosynthesis system, received its CE Mark in February 2025 and is cleared for commercialization across the EU. The deployment advances Nanox’s European clinical validation program and commercial presence. Olympe Imagerie’s centers collectively serve more than 400,000 outpatients, inpatients, and visitors annually, offering significant clinical exposure for trial activities.

Positive

• CE Mark obtained in February 2025
• Deployment at Hospital Privé Jacques Cartier MASSY in Paris metro
• Clinical access to >400,000 patients annually via Olympe Imagerie sites

Negative

• Clinical trials ongoing; commercial benefit not yet validated

Insights

Clinical-commercial strategist

Partnership advances European clinical validation and initial deployment of the CE‑marked Nanox.ARC for lung cancer screening.

Nanox secures a direct clinical pathway into the Paris region by placing a Nanox.ARC at Hospital Privé Jacques Cartier MASSY alongside the independent radiology group Olympe Imagerie. The arrangement creates immediate access to a multisite patient base (stated >400,000 annual visits) and sets up prospective clinical trials to evaluate tomosynthesis performance specifically for lung cancer detection.

The value hinges on three concrete facts: the device has a Feb 2025 CE Mark enabling EU commercialization, the system is en route to France, and the deployment targets lung cancer screening use‑cases. Key risks include the unknown design and endpoints of the planned trials and the lack of disclosed clinical performance data in this announcement, so clinical or commercial lift is not yet demonstrated.

Watch for trial milestones and outputs within a 6–18 month horizon: trial protocol details, primary endpoint definitions, site initiation dates, interim sensitivity/specificity metrics, and any regulatory or reimbursement steps in France. Those items will determine whether this partnership translates into meaningful clinical evidence and commercial uptake.

Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Privé Jacques Cartier MASSY for lung cancer screening applications

PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration with Olympe Imagerie, a Paris-based group of independent radiologists, to deploy the Nanox.ARC and expand its clinical research evidence generation program in France.

The Nanox.ARC system is already on its way to France, marking an important progress as Nanox strengthens its European clinical and commercial presence.

Under the collaboration, the Nanox.ARC system will be deployed at Hospital Privé Jacques Cartier MASSY, one of the leading private hospital groups in the Paris metropolitan area, for clinical trials designed to further assess the value of the Nanox.ARC in supporting lung cancer detection, management, and screening.

The Nanox.ARC is a multi-source digital tomosynthesis system that utilizes advanced 3D imaging technology to provide enhanced diagnostic capabilities at a lower cost than traditional systems. Following its CE Mark certification in February 2025, the Nanox.ARC is cleared for commercialization across the European Union.

Olympe Imagerie is an independent radiology group whose physicians provide imaging services at multiple centers across the Ile-de-France region in Antony, Massy and Dourdan. Collectively, these sites serve more than 400,000 outpatients, inpatients, and visitors each year.

“France is an important market for our European expansion strategy, and this collaboration advances our clinical validation efforts in a key geography,” said Erez Meltzer, CEO and Acting Chairman of Nanox. “By partnering with Olympe Imagerie and Hospital Privé Jacques Cartier MASSY, we’re positioning the Nanox.ARC to demonstrate its potential value in lung cancer screening, an important application where early detection can significantly improve patient outcomes.”

Romain Pommier, Associate Radiologist at Olympe Imagerie, said, “We are proud to collaborate with Nanox and to be among the first in Europe to evaluate this new and cutting-edge imaging system. helping us bring more inclusive and effective diagnostic solutions to patients. Lung cancer screening remains one of the most important applications in diagnostic radiology, and we’re excited to evaluate how the Nanox.ARC’s tomosynthesis capabilities can potentially enhance our ability to detect lung abnormalities earlier and more accurately. This collaboration is an important step in bringing advanced, accessible imaging technology to our patient population.”

About Nanox

Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.

Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI to enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective and user-friendly; Nanox.AI LTD – an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Contacts

Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com

Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com

FAQ

What did Nanox (NNOX) announce on November 14, 2025 about European expansion?

Nanox announced a collaboration with Olympe Imagerie to deploy the Nanox.ARC at Hospital Privé Jacques Cartier MASSY to advance lung cancer screening clinical trials in France.

Has the Nanox.ARC received regulatory clearance in Europe for commercialization?

Yes. The Nanox.ARC received a CE Mark in February 2025 and is cleared for commercialization across the EU.

Which hospital will host the Nanox.ARC trials and what is the expected patient reach?

Hospital Privé Jacques Cartier MASSY will host the device; Olympe Imagerie’s sites serve over 400,000 outpatients, inpatients, and visitors annually.

What clinical application will Nanox evaluate with Olympe Imagerie and Hospital Privé Jacques Cartier MASSY?

The collaboration will evaluate the Nanox.ARC’s use in lung cancer detection, management, and screening through designed clinical trials.

Will the Nanox.ARC deployment immediately affect Nanox (NNOX) revenue?

The announcement describes clinical trials and EU commercialization clearance, but it does not report immediate revenue or financial guidance.